TIRZEPATIDE
- ≥99% purity by HPLC
- Janoshik COA with every lot
- Lot-traceable from synthesis
- EU-synthesised
Specifications
Third Party Lab Tested
Every lot is independently HPLC-tested by Janoshik Analytical, Europe's reference laboratory for peptide purity assessment. The COA shipped with your order is theirs, not ours.
Storage & Handling
Lyophilized peptides should be stored below 16°C, protected from light and moisture, for up to 24 months. Once reconstituted, refrigerate and use within 30 days for protocol consistency.
Reconstitution
Reconstitute with bacteriostatic water using the volumes below. Add solvent slowly along the inside wall of the vial. Swirl gently, never shake, until fully dissolved.
Lab-handling protocol BAC Water · 0.9% benzyl alcohol The reconstitution solvent referenced above. Add to order →The dual agonist
benchmark.
Tirzepatide is the most-studied GLP-1 / GIP dual agonist in metabolic research. Activating both receptors simultaneously produces a steeper glycemic response curve and stronger satiety signaling than GLP-1 alone - the basis for nearly every modern incretin-mimetic protocol design.
Lot-to-lot reproducibility is the primary reason researchers source TIRZEPATIDE from us. Each lot is HPLC-MS verified at ≥99% purity by Janoshik Analytical, with full sequence and mass-match documentation in the Certificate of Analysis.
| Compound | Tirzepatide |
|---|---|
| Sequence length | 39 amino acids |
| Molecular mass | 4813.5 Da |
| Modeled half-life | ~5 days (modeled) |
| Mechanism / research class | Dual GLP-1R / GIPR agonist. |
| Lab handling solvent | 2mL bacteriostatic water for injection (BWI) |
| Resulting concentration | Yields 5mg per 1.0mL |
| Supply format | Tirzepatide · 10MG · GLP-1/GIP lyophilized research vial |
| Storage, lyophilized | store below 16°C for up to 24 months |
| Storage, reconstituted | refrigerate and use within 30 days |
Synthesised.
Verified.
Documented.
Backed by research.
Measured in results.
Each tag opens the cited literature behind that effect. References are linked to PubMed.
Tirzepatide is a 39-amino-acid GLP-1 / GIP dual agonist. The dual receptor profile produces a steeper satiety-pathway response than single-pathway GLP-1, with downstream effects on body weight and adiposity in both research models and published clinical literature.
The reference SURMOUNT-1 trial reported a mean body-weight reduction of −22.5% from baseline at 72 weeks in the highest published study arm, with monotonic responses across published study arms. Results referenced for in-vitro / animal-model protocol design only.
GLP-1 / GIP dual agonism amplifies insulin secretion and steepens the glycemic-response curve compared with single-pathway GLP-1 agonism. The reference literature reports HbA1c reductions of 1.87% to 2.59% across published weekly study arms in T2D research populations.
- Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes. The Lancet. 2021;398(10295):143-155. PubMed ↗
GLP-1 / GIP co-agonism engages hepatic lipid handling beyond what GLP-1 alone produces. The Tirzepatide MASLD substudy reported relative liver-fat reduction of up to 73% at 52 weeks measured by MRI-PDFF in the highest published study arm.
- Hartman ML et al. Effects of tirzepatide on biomarkers of NAFLD/NASH in patients with T2D. Diabetes Care. 2020;43(6):1352-1355. PubMed ↗
Beyond direct glycemic effects, dual incretin agonism improves measured markers of insulin sensitivity (HOMA-IR) and metabolic flexibility in research populations - a profile that distinguishes Tirzepatide from single-pathway references in published comparison studies.
- Frías JP et al. SURPASS-2 trial. NEJM. 2021;385(6):503-515. PubMed ↗
Questions?
We got answers.
Show references
Used in published research.
4.8 / 5
Solid product, fast EU shipping
Ordered TIRZEPATIDE for a research-protocol pilot. Arrived in 4 days temperature-controlled, vials sealed and properly lyophilized. Reconstituted cleanly in BWI with no haze. Will reorder.
